Close Notification

Your cart does not contain any items

Next Generation Biomarkers

From Omics to Precision Medicine

Wim Van Criekinge (Professor of Bioinformatics, University of Ghent, Belgium)



Not in-store but you can order this
How long will it take?


Academic Press Inc
01 September 2019
Next Generation Biomarkers: From Omics to Precision Medicine offers a clear methodology for successfully discovering and validating biomarkers using next generation sequencing, along with a comprehensive overview of next generation biomarkers currently used in the clinic. With recent advances in genomics and -omics approaches, elaborative molecular profiling is increasingly employed to gain fundamental insights into disease etiology and progression. Through a case-study based approach, the book examines a variety of NGS genomic and omics approaches to biomarker discovery and validation, along with lessons learned from recent studies and clinical trials.

Chapters explore common challenges, regulations and strategies for more accurate and efficient development of next generation biomarkers, and NGS approaches, ranging from whole exome sequencing, to whole genome sequencing, epigenomic profiling, transcriptomics, peptidomics, proteomics, liquid biopsy, ethical considerations, and patient empowerment in biomarker development.
Edited by:   Wim Van Criekinge (Professor of Bioinformatics University of Ghent Belgium)
Imprint:   Academic Press Inc
Country of Publication:   United States
Dimensions:   Height: 235mm,  Width: 191mm, 
ISBN:   9780128143155
ISBN 10:   0128143150
Pages:   400
Publication Date:   01 September 2019
Audience:   Professional and scholarly ,  Undergraduate
Format:   Paperback
Publisher's Status:   Active

Dr. Wim Van Criekinge graduated in 1994 as a Chemical Engineer from the University of Ghent, Belgium, where he also earned his PhD in Molecular Biology in 1998. Today he holds a part-time Professorship at the same university, where he is head of the laboratory for computational genomics and bioinformatics (Biobix) within the department of molecular biotechnology. He is a founding partner of NXT-GNT, a next generation sequencing facility and board member of N2N (nucleotides 2 networks), a multidisciplinary platform grouping systems biology expertise at the University of Ghent. In 1997 he was co-founder and director of Devgen, a biotechnology company, which had a successful IPO in June 2005. Dr. Van Criekinge has also worked as a consultant for the government (iHealth) and various biotech companies, and he currently serves as VP of Science & Technology at MDx-Health. Dr. Van Criekinge has published over 130 peer reviewed papers in topics ranging from epigenetics to biotechnology, translational medicine, bioinformatics, ICT, pharmacogenomics, eHealth, biobanking, omics, and biomarker research.

See Also